State-based Reform
-
340B, Caught my eye, COVID, Drug Prices, Medicaid, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Pharmacy Benefit Managers, Reference Pricing, State-based Reform, VaccinesAMP is WAC — 05/30/25
Read more: AMP is WAC — 05/30/25I do love a Monday off. It somehow feels like an a double-treat – you get the Monday off and the week flies by. Yes we had to cram more meetings and work into the shorter week but totally worth it. Caught my Eye Processed Over. This week the Secretary of Health and Human Services,…
-
340B, Alzheimer’s, Biosimilars, Caught my eye, Drug Prices, Generics, Healthcare Costs, Importation, Medicaid, State-based ReformAMP is WAC — 05/23/25
Read more: AMP is WAC — 05/23/25It’s the Friday of Memorial Day weekend, let’s blow this pop (pup?) stand. I’m playing with the format of these posts so let me know what you think. The aim is to be more of a newsletter than a blog, but still give you everything you need to know in just a few minutes a…
-
340B, Caught my eye, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based ReformCaught my eye — 4/25/25
Read more: Caught my eye — 4/25/25Let’s Get Horizontal. Arkansas just passed a law banning pharmacy benefit managers (PBMs) from owning pharmacies in the state. Other states like Vermont and New York are considering it. This also includes mail order and specialty pharmacy. Lately the economics of independent pharmacies are getting covered in the media showcasing how they often lose money…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicare Negotiation, Medicare Transaction Facilitator, Medicare Transaction Facilitator, Pharmacy Benefit Managers, State-based Reform, UncategorizedCaught my eye — 4/4/25
Read more: Caught my eye — 4/4/25Mom and Pop Going Broke. The economics of pharmacies are fascinating. Like did you know they usually lose money on brand-name drugs? A pharmacy benefit manager (PBM) law in Montana would help those pharmacies get closer to at least breaking even and make sure they get dispensing fees. I thought this KFF piece was a…
-
Caught my eye, Generics, Healthcare Costs, ICER, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan Drugs, State-based Reform, ValueCaught my eye — 03/07/25
Read more: Caught my eye — 03/07/25Tuesday morning, I spent the first half of the day convinced it was Wednesday, and yet, despite that mental setback, the rest of the week has flown by. Feels like a win. Killing me softly. Overall, glad to see the stories recognizing how the uncertainty of federal research dollars is impacting NIH summer internships, graduate…
-
Caught my eye — 10/25/24
Read more: Caught my eye — 10/25/24Caught my eye .. This week I am struck by connections between 340B and pharmacy benefit managers (PBMs) in terms of being issue areas that need complete makeovers. A glow up won’t do; we’re beyond that. But the trajectory toward change is very different. PBMs and payers (maybe) benefit from the way PBMs currently work.…
-
Caught my eye, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, State-based Reform, UncategorizedCaught my eye — 08/02/24
Read more: Caught my eye — 08/02/24Up, up and away. Earlier this week, the Centers for Medicare & Medicaid Services (CMS) announced initial premium information for the 2025 Medicare prescription drug benefit. The base beneficiary premium went up 6% or $2.08 to $36.78. Which sounds okay until you realize that 6% is a capped amount due to the Inflation Reduction Act.…
-
Caught my eye — 6/14/24
Read more: Caught my eye — 6/14/24Summer vibes are real in the DC area this week with schools letting out and pool time kicking in. College wood bat baseball league games are on, and the summer night hang out is in full swing. I don’t know if it is my mood or the season or both, but things seem a little…
-
Caught my eye — 06/07/24
Read more: Caught my eye — 06/07/24A relatively quiet week around these parts. I think everyone is so ASCO’d and BIO’d that policy is taking a quick breather. A PDAB will do you. The National Pharmaceutical Council put out a nice round-up comparing four prescription drug affordability boards. The chart is my favorite part – Extra, extra. Elevance Health, a health…
-
Getting nowhere fast
Read more: Getting nowhere fastMy mom said to never use the word hate but, honestly, I hate step therapy. I dislike prior authorization but step therapy, well I hate it. Both fall under the concept of utilization management which are barriers to access put up by payers (really pharmacy benefit managers (PBMs)) for cost or safety concerns. The idea…
Latest news
- AMP is WAC — 06/06/25
- AMP is WAC — 05/30/25
- AMP is WAC — 05/23/25
- Caught my eye — 5/16/25
- Initial Take on MFN Executive Order, Part II
Categories
- 340B (41)
- Affordable Care Act (6)
- Alzheimer's (7)
- Biosimilars (23)
- Caught my eye (70)
- Cell and Gene (2)
- Chevron Deference (2)
- CMMI (14)
- Copay Accumulators (6)
- COVID (3)
- Drug Prices (39)
- Drug shortages (10)
- DTC (2)
- Employers (9)
- Generics (7)
- Health Equity (3)
- Healthcare Costs (32)
- ICER (10)
- Importation (5)
- Inflation Reduction Act (50)
- Insulin (5)
- IP (3)
- Long term care (1)
- Medicaid (9)
- Medicare Advantage (16)
- Medicare Negotiation (53)
- Medicare Part D (48)
- Medicare Transaction Facilitator (3)
- Medicare Transaction Facilitator (10)
- Obesity (21)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (33)
- Preventative (2)
- Reference Pricing (9)
- State-based Reform (18)
- Supply Chain (2)
- Uncategorized (7)
- Utilization Management (1)
- Vaccines (5)
- Value (13)